ArticleFrontiers in psychiatry2025
The burden of attention deficit hyperactivity disorder and incidence rate forecast in China from 1990 to 2021.
Article in Frontiers in psychiatry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Article
- Trends in the burden of road traffic injuries among children and adolescents aged 0-19 years in low- and middle-income countries, 1990-2023.Journal of global health · 2026Article
- A Network Analysis of ADHD and ASD Symptoms in Chinese Children: Insights on Age and Gender Differences.International journal of methods in psychiatric research · 2025Article
- The impact of a multi-micronutrient nutritional formula combined with cognitive behavioral therapy in managing symptoms of children with attention deficit hyperactivity disorder.Frontiers in pediatrics · 2025Article
- Trends in incidence, prevalence, and disability-adjusted life years of schizophrenia in China from 1990 to 2021, with projections for 2022-2050.Frontiers in psychiatry · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To analyze the temporal trends and future projections of attention-deficit/hyperactivity disorder (ADHD) burden among children and adolescents in China from 1990 to 2021, and to identify age-, period-, and cohort-specific drivers of disease progression. Methods: Using data from the Global Burden of Disease Study 2021, we conducted joinpoint regression to detect trend transitions in ADHD incidence and age-standardized rates. Age-period-cohort (APC) modeling was applied to disentangle the effects of age, calendar period, and birth cohort on disease burden. Projections up to 2046 were generated using demographic forecasts from the GBD 2017 population database. Results: Crude ADHD prevalence declined by 21.17% (2168.055 to 1723.307 per 100,000), yet age-standardized prevalence increased by 9.86% (AAPC=0.272%, 95%CI:0.173-0.372, P<0.001). Similarly, age-standardized DALY rates rose by 10.15% (AAPC=0.262%, 95%CI:0.160-0.364,P<0.001), with females showing faster growth than males (AAPC for DALY: 0.294% vs. 0.229%,P<0.001). Adolescents aged 10-14 years bore the highest burden, with prevalence (5,727.28/100,000) and DALY rates (70.55/100,000) twice the global average. APC projections indicated a peak incidence in 2029 for this age group, linked to cohort effects from China's "Double Reduction" education policy and rising digital exposure. Conclusion: China faces a rising ADHD burden driven by sociodemographic transitions and diagnostic advancements. Targeted interventions-particularly for adolescents and females-are urgently needed. Strengthening school-based screening, integrating AI-driven diagnostic tools, and prioritizing mental health in national policies could mitigate long-term impacts. These findings underscore the necessity of dynamic surveillance systems to address ADHD's evolving epidemiology in transitioning societies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.